Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT
Autor: | David Sebag-Montefiore, R. Frood, Alexandra Gilbert, Ane L Appelt, Jim Zhong, Peter Brown, Andrew Scarsbrook, S. Currie |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Pre treatment
medicine.medical_specialty business.industry Incidence (epidemiology) Anal Squamous Cell Carcinoma General Medicine Outcome prediction Logistic regression FDG-PET/CT 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Anal squamous cell carcinoma (ASCC) Radiomic feature analysis 030220 oncology & carcinogenesis Cohort medicine Radiology Nuclear Medicine and imaging Fdg pet ct Original Article Radiology Stage (cooking) business Chemoradiotherapy |
Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging |
ISSN: | 1619-7089 1619-7070 |
Popis: | Purpose Incidence of anal squamous cell carcinoma (ASCC) is increasing, with curative chemoradiotherapy (CRT) as the primary treatment of non-metastatic disease. A significant proportion of patients have locoregional treatment failure (LRF), but distant relapse is uncommon. Accurate prognostication of progression-free survival (PFS) would help personalisation of CRT regimens. The study aim was to evaluate novel imaging pre-treatment features, to prognosticate for PFS in ASCC. Methods Consecutive patients with ASCC treated with curative intent at a large tertiary referral centre who underwent pre-treatment FDG-PET/CT were included. Radiomic feature extraction was performed using LIFEx software on baseline FDG-PET/CT. Outcome data (PFS) was collated from electronic patient records. Elastic net regularisation and feature selection were used for logistic regression model generation on a randomly selected training cohort and applied to a validation cohort using TRIPOD guidelines. ROC-AUC analysis was used to compare performance of a regression model encompassing standard clinical prognostic factors (age, sex, tumour and nodal stage—model A), a radiomic feature model (model B) and a combined radiomic/clinical model (model C). Results A total of 189 patients were included in the study, with 145 in the training cohort and 44 in the validation cohort. Median follow-up was 35.1 and 37. 9 months, respectively for each cohort, with 70.3% and 68.2% reaching this time-point with PFS. GLCM entropy (a measure of randomness of distribution of co-occurring pixel grey-levels), NGLDM busyness (a measure of spatial frequency of changes in intensity between nearby voxels of different grey-level), minimum CT value (lowest HU within the lesion) and SMTV (a standardized version of MTV) were selected for inclusion in the prognostic model, alongside tumour and nodal stage. AUCs for performance of model A (clinical), B (radiomic) and C (radiomic/clinical) were 0.6355, 0.7403, 0.7412 in the training cohort and 0.6024, 0.6595, 0.7381 in the validation cohort. Conclusion Radiomic features extracted from pre-treatment FDG-PET/CT in patients with ASCC may provide better PFS prognosis than conventional staging parameters. With external validation, this might be useful to help personalise CRT regimens in the future. Electronic supplementary material The online version of this article (10.1007/s00259-019-04495-1) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |